Valuation: Orexo AB

Market Cap 829M 85.76M 75.05M 69.17M 64.11M 122M 8.14B 124M 323M 4.02B 322M 315M 13.89B P/E 2026 *
-2.63x
P/E 2027 * -3.29x
Enterprise Value 631M 65.29M 57.14M 52.66M 48.81M 92.65M 6.2B 94.14M 246M 3.06B 245M 240M 10.57B EV / Sales 2026 *
24.3x
EV / Sales 2027 * 25.5x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day-2.46%
1 week-1.04%
Current month-1.04%
1 month+25.53%
3 months+17.00%
6 months-30.96%
Current year-21.10%
1 week 23
Extreme 23
25.35
1 month 18.62
Extreme 18.62
25.45
Current year 17.52
Extreme 17.52
36
1 year 17.5
Extreme 17.5
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 04/02/2013
Director of Finance/CFO 59 31/08/2022
Chief Tech/Sci/R&D Officer - 30/09/2024
Director TitleAgeSince
Director/Board Member 64 31/12/2001
Director/Board Member 70 10/04/2019
Director/Board Member 62 31/03/2022
Date Insider Type Main position Quantity % Market Cap.
03/09/25Buy

Chief Executive Officer

6 0.0000%
03/09/25Free

Chief Executive Officer

1,393 0.0040%
02/09/25Buy 1 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%-1.04%+18.45%+60.47% 88.06M
+1.64%+0.28%+59.28%+18.22% 313B
-0.74%-3.47%+29.63%-3.24% 70.89B
+0.98%+4.22%+50.44%+122.75% 9.58B
-1.71%+3.15%+6.57%+1.68% 8.82B
+1.07%-6.81%-7.11%+9.27% 4.29B
-5.65%+0.56%+11.76%+23.41% 4.25B
+1.01%-4.74%-33.99%+27.27% 3.39B
+1.48%+3.07%+52.43%+61.74% 2.74B
-2.91%-1.09%+13.77%-21.96% 2.22B
Average -0.73%-0.27%+20.12%+29.96% 41.94B
Weighted average by Cap. +1.04%-1.92%+50.75%+16.75%

Financials

2026 *2027 *
Net sales 26M 2.69M 2.35M 2.17M 2.01M 3.82M 255M 3.88M 10.11M 126M 10.09M 9.88M 435M 27M 2.79M 2.44M 2.25M 2.09M 3.96M 265M 4.03M 10.5M 131M 10.48M 10.25M 452M
Net income -322M -33.3M -29.14M -26.85M -24.89M -47.25M -3.16B -48.01M -125M -1.56B -125M -122M -5.39B -259M -26.78M -23.44M -21.6M -20.02M -38.01M -2.54B -38.62M -101M -1.25B -101M -98.37M -4.34B
Net Debt -198M -20.47M -17.92M -16.51M -15.31M -29.05M -1.94B -29.52M -77M -959M -76.87M -75.2M -3.31B -142M -14.68M -12.85M -11.84M -10.98M -20.84M -1.39B -21.17M -55.22M -688M -55.13M -53.93M -2.38B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
65
Date Price Change Volume
07/07/26 SEK 23.75 -2.46% 4,817
06/07/26 SEK 24.35 +0.41% 11,326
03/07/26 SEK 24.25 -0.21% 12,759
02/07/26 SEK 24.30 +2.97% 18,971
01/07/26 SEK 23.60 -1.67% 13,849
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise